HRP20151356T1 - Postupci za poboljšanje adjuvantnosti pripravaka za cjepiva - Google Patents

Postupci za poboljšanje adjuvantnosti pripravaka za cjepiva Download PDF

Info

Publication number
HRP20151356T1
HRP20151356T1 HRP20151356TT HRP20151356T HRP20151356T1 HR P20151356 T1 HRP20151356 T1 HR P20151356T1 HR P20151356T T HRP20151356T T HR P20151356TT HR P20151356 T HRP20151356 T HR P20151356T HR P20151356 T1 HRP20151356 T1 HR P20151356T1
Authority
HR
Croatia
Prior art keywords
vaccine preparation
use according
subject
antigen
immune response
Prior art date
Application number
HRP20151356TT
Other languages
English (en)
Croatian (hr)
Inventor
Vincent Serra
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of HRP20151356T1 publication Critical patent/HRP20151356T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HRP20151356TT 2007-08-29 2008-08-29 Postupci za poboljšanje adjuvantnosti pripravaka za cjepiva HRP20151356T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96873107P 2007-08-29 2007-08-29
EP08875737.2A EP2190475B1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions
PCT/IB2008/003016 WO2010023498A1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Publications (1)

Publication Number Publication Date
HRP20151356T1 true HRP20151356T1 (hr) 2016-01-01

Family

ID=42061962

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151356TT HRP20151356T1 (hr) 2007-08-29 2008-08-29 Postupci za poboljšanje adjuvantnosti pripravaka za cjepiva

Country Status (14)

Country Link
US (1) US8916164B2 (enExample)
EP (1) EP2190475B1 (enExample)
JP (1) JP5539890B2 (enExample)
KR (1) KR101540081B1 (enExample)
CN (1) CN101820909A (enExample)
AU (1) AU2008360937B9 (enExample)
BR (1) BRPI0815846A2 (enExample)
ES (1) ES2558157T3 (enExample)
HR (1) HRP20151356T1 (enExample)
PL (1) PL2190475T3 (enExample)
PT (1) PT2190475E (enExample)
RU (1) RU2491090C2 (enExample)
WO (1) WO2010023498A1 (enExample)
ZA (1) ZA201001477B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008350531B2 (en) 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
ES2617510T3 (es) 2012-04-26 2017-06-19 Riken Nuevo carbamato de glicolípido y uso del mismo
WO2022187141A1 (en) 2021-03-01 2022-09-09 Deciduous Therapeutics Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
KR100281264B1 (ko) 1992-10-22 2001-02-01 마나배 게이사꾸 신규한 스핀고당 지질 및 그의 사용
CN1045302C (zh) 1993-04-15 1999-09-29 麒麟麦酒株式会社 新型(神经)鞘糖脂、含有它们的药物组合物及其用途
CA2162478A1 (en) 1993-05-14 1994-11-24 Shawn A. Defrees Sialyl lex analogues as inhibitors of cellular adhesion
US6054433A (en) 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
WO1998034623A1 (en) 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Freeze-dried composition containing glycosphingolipid and process for producing the same
ES2235324T3 (es) 1997-04-10 2005-07-01 Kirin Beer Kabushiki Kaisha Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes.
AU750141B2 (en) 1997-12-30 2002-07-11 A+ Science Invest Ab Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
AU765809B2 (en) 1998-02-12 2003-10-02 Emory University Sphingolipid derivatives and their methods of use
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
WO2001026683A2 (en) * 1999-10-12 2001-04-19 National Research Council Of Canada Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2001082935A1 (fr) 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedes contre le cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
AU2001268564A1 (en) 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
RU2360699C2 (ru) * 2001-10-03 2009-07-10 Новартис Вэксинес Энд Дайэгностикс Инк. Композиции менингококковых вакцин с адъювантами
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
EP1611147A4 (en) 2003-03-20 2007-10-17 Univ Brigham Young 6 "amino-6" -DEOXYGALACTOSYLCERAMIDE
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US20050222048A1 (en) 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
DK1786439T3 (da) 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
EP1833489A4 (en) 2004-12-28 2011-08-03 Univ Rockefeller GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS
US9295722B2 (en) 2005-01-28 2016-03-29 The Scripps Research Institute Bacterial glycolipid activation of CD1d-restricted NKT cells
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
WO2007050668A1 (en) 2005-10-25 2007-05-03 Ludwig Institute For Cancer Research Analogs of alpha galactosylceramide and uses thereof
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
EP2029165B1 (en) 2006-04-27 2014-12-03 Cellid Co., Ltd B cell-based vaccine loaded with the ligand of natural killer t cell and antigen
JP5564672B2 (ja) 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2008350531B2 (en) 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
CN102215864A (zh) 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物

Also Published As

Publication number Publication date
JP5539890B2 (ja) 2014-07-02
AU2008360937B2 (en) 2014-01-16
US8916164B2 (en) 2014-12-23
KR20100072211A (ko) 2010-06-30
KR101540081B1 (ko) 2015-07-29
RU2491090C2 (ru) 2013-08-27
AU2008360937A1 (en) 2010-03-04
AU2008360937A2 (en) 2010-04-29
US20100285042A1 (en) 2010-11-11
ZA201001477B (en) 2010-12-29
BRPI0815846A2 (pt) 2017-05-30
JP2011518760A (ja) 2011-06-30
PT2190475E (pt) 2016-02-11
WO2010023498A1 (en) 2010-03-04
RU2010111766A (ru) 2011-10-10
CN101820909A (zh) 2010-09-01
EP2190475A1 (en) 2010-06-02
EP2190475B1 (en) 2015-10-28
AU2008360937B9 (en) 2014-02-13
PL2190475T3 (pl) 2016-04-29
WO2010023498A8 (en) 2010-04-15
ES2558157T3 (es) 2016-02-02

Similar Documents

Publication Publication Date Title
US11167020B2 (en) Pneumococcal dosing regimen
Ilyinskii et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release
RU2434638C2 (ru) Вакцина альфа токсоида с.perfringens
TW200722101A (en) Novel composition
Ada et al. Carbohydrate—protein conjugate vaccines
Reed et al. Correlates of GLA family adjuvants’ activities
Montomoli et al. Current adjuvants and new perspectives in vaccine formulation
CR10559A (es) Vacuna de influenza
Friedlander et al. Advances in the development of next-generation anthrax vaccines
JP2010163453A5 (enExample)
RU2005127200A (ru) Менингококковые вакцины для введения через слизистую оболочку
JP2017523180A (ja) フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
MX355366B (es) Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
JP2007534728A5 (enExample)
RU2013114980A (ru) Вакцинная композиция
JP2012001565A5 (enExample)
JP2018501322A5 (enExample)
HRP20151356T1 (hr) Postupci za poboljšanje adjuvantnosti pripravaka za cjepiva
RU2010127339A (ru) Композиции и способы для усиления иммунного ответа на антигены
Jonsdottir Maturation of mucosal immune responses and influence of maternal antibodies
Parmaksız et al. Development of multistage recombinant protein vaccine formulations against toxoplasmosis using a new chitosan and porin based adjuvant system
JP2011518760A5 (enExample)
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2017084518A1 (zh) 一种疫苗佐剂以及包含该佐剂的疫苗
Sisteré-Oró et al. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate